All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Rilvegostomig Elicits Responses in CPI-Naive NSCLC, Irrespective of PD-L1 TPS Status

September 10th 2024

Rilvegostomig induced responses with acceptable tolerability in patients with checkpoint inhibitor-naive, metastatic NSCLC.

Dr Leighl on Patient Satisfaction and Resource Utilization From PALOMA-3 in NSCLC

September 10th 2024

Natasha B. Leighl, MD, BSc, MMSc, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study.

Mayo Clinic Study Finds Dysfunctional White Blood Cells Linked to Heightened Melanoma Risk

September 10th 2024

About 8 to 10 million Americans over 40 have excess white blood cells, which may increase their risk of melanoma.

THIO Followed by Cemiplimab Leads to Potential OS Benefit in Pretreated Advanced NSCLC

September 10th 2024

THIO followed by cemiplimab generated a potential overall survival benefit in third-line advanced non–small cell lung cancer.

HER2DX Shows Correlation Between ERBB2 mRNA Levels and Survival in HER2+ Breast Cancer

September 10th 2024

HER2DX showed a strong association between ERBB2 mRNA score and survival outcomes in tumor samples from patients with advanced HER2-positive breast cancer.

Real-World Data for Pacritinib Show Improvement in Thrombocytopenia, Anemia in Myelofibrosis

September 10th 2024

Pacritinib led to improved hematologic outcomes and overall survival in real-world patients with myelofibrosis.

Proteomics and Prognostics May Serve as Potential Biomarkers Beyond PD-L1 in Lung Cancer

September 10th 2024

Luis Raez, MD, details several potential lung cancer biomarkers under investigation including the plasma proteomics–based PROphet test.

FDA Approval of Amivantamab Plus Lazertinib Builds Upon Success of First-Line TKIs in Advanced EGFR-Mutant NSCLC

September 10th 2024

Joshua K. Sabari, MD, discusses the significance of the FDA approval of first-line amivantamab plus lazertinib for patients with EGFR-mutant NSCLC.

Analysis Further Shows Perioperative Pembrolizumab Efficacy in Early-Stage NSCLC

September 9th 2024

Neoadjuvant pembrolizumab plus chemotherapy led to greater pathologic regression vs placebo plus chemotherapy in early-stage non–small cell lung cancer.

Osimertinib Plus Savolitinib Exhibits Clinically Meaningful ORR vs Osimertinib in EGFR+ NSCLC

September 9th 2024

The combination of osimertinib/savolitinib demonstrated a significant improvement in ORR in de novo MET-aberrant, EGFR-mutant advanced NSCLC.

Firmonertinib Shows Antitumor Activity in EGFR PACC-Mutated NSCLC

September 9th 2024

Treatment with firmonertinib was safe and effective for patients with EGFR P-loop and αC-helix compressing-mutated non–small cell lung cancer.

Aumolertinib Improves PFS in Unresectable, Stage III EGFR+ NSCLC after Chemoradiotherapy

September 9th 2024

Treatment with aumolertinib led to an improvement in progression-free survival in unresectable, stage III, EGFR-mutated non–small cell lung cancer.

Zanubrutinib Associated With Lower Switching Rates vs Other Covalent BTK Inhibitors in CLL/SLL

September 9th 2024

Zanubrutinib was associated with lower treatment switching rates vs acalabrutinib and ibrutinib in real-world chronic lymphocytic leukemia.

Zongertinib Demonstrates Clinically Meaningful Efficacy in HER2-Mutated NSCLC

September 9th 2024

Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.

BAY 2927088 Displays Durable Responses in HER2-Mutated NSCLC

September 9th 2024

BAY 2927088 demonstrated durable response rates for patients with pretreated HER2-mutant non–small cell lung cancer.

Sacituzumab Govitecan Generates Responses With Manageable Safety Profile in ES-SCLC

September 9th 2024

Treatment with sacituzumab govitecan in the second-line setting yielded antitumor activity in patients with extensive-stage small cell lung cancer.

Dr Wu on SAFFRON-301 Data in Advanced or Metastatic NSCLC

September 9th 2024

Yi-Long Wu, MD, PhD, discusses findings from the phase 3 SAFFRON-301 trial in patients with advanced or metastatic NSCLC.

Dato-DXd Misses OS End Point in TROPION-Lung01 Study for NSCLC

September 9th 2024

Dato-DXd did not significantly improve overall survival compared with docetaxel for patients with non–small cell lung cancer.

HS-20093 Generates Responses in Pretreated ES-SCLC

September 9th 2024

HS-20093 produced responses in extensive-stage small cell lung cancer after prior platinum-based chemotherapy with or without prior immunotherapy.

Early Data Show Complete Responses With Elraglusib Combination in Ewing Sarcoma

September 9th 2024

Elraglusib plus chemotherapy generated early signals of antitumor activity in pediatric patients with relapsed/refractory Ewing and Ewing-related sarcomas.